GO
| HSI1 | 26,545.10 | +0.25 | 376.81B |
| HSCEI1 | 9,472.35 | +15.83 | 129.31B |
| Back Zoom + Zoom - Block Traded | |
|
1st Patient in Australia Dosed in HENLIUS' Phase 2 Clinical Study of HLX43
2025-09-18 17:36:22 Recently, the first patient in Australia has been dosed in an international multicentre phase 2 clinical study of HLX43 for injection (an anti-PD-L1 antibody-drug conjugate) in patients with advanced non-small cell lung cancer (NSCLC), according to HENLIUS (02696.HK)'s announcement. This phase 2 clinical study is also ongoing in mainland China and the US. ~ AASTOCKS Financial News Website: www.aastocks.com | |